<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DORYX- doxycycline hyclateÂ tablet, delayed releaseÂ </strong><br>Warner Chilcott (US), LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use DORYX<span class="Sup">Â®</span> (doxycycline hyclate delayed-release tablets) safely and effectively. See Full Prescribing Information for DORYX Tablets.<br><br>DORYX<span class="Sup">Â®</span> (doxycycline hyclate delayed-release tablets), 100 mg, 150 mg, and 200 mg for Oral use. <br>Initial U.S. Approval: 1967<br><br>
</div>
<div><div><p class="Highlighta">To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate and other antibacterial drugs, DORYX Tablets should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria. (<a href="#i4i_indications_id_4e681f01-9fb8-4998-84ac-97f2ec3f3f43">1</a>)<br><br> </p></div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Dosage and Administration (<a href="#i4i_section_id_447e73d9-82af-4a49-b5e8-c8f41c9dff04">2.1</a>) Â Â Â  Â Â Â Â  Â Â Â Â  04/2013 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">DORYX is a tetracycline-class antimicrobial indicated for:  </p>
<ul>
<li>Rickettsial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<a href="#i4i_section_id_2d63d51d-f189-4214-b1f2-1257cadf0dcd">1.1</a>) </li>
<li>Sexually transmitted <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<a href="#i4i_section_id_d34328b3-fbab-4d15-be0f-c9ac5a0dd818">1.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> (<a href="#i4i_section_id_52b37ce9-5e74-477a-8364-8bf665b92ec5">1.3</a>)</li>
<li>Specific <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> (<a href="#i4i_section_id_3fb6aa54-c16e-421f-99c8-e3a5e2122682">1.4</a>) </li>
<li>Ophthalmic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<a href="#i4i_section_id_95f2a5bd-7a01-4bb3-aef6-31cdfbb00df8">1.5</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span>, including inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure) (<a href="#i4i_section_id_94d1dd7e-3c83-4cd0-8ff2-6911b2873a3a">1.6</a>)</li>
<li>Alternative treatment for selected <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> when penicillin is contraindicated (<a href="#i4i_section_id_9b2454b8-a5f3-4d33-b61b-de6705b3fa55">1.7</a>)</li>
<li>Adjunctive therapy in acute intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> and severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> (<a href="#i4i_section_id_f161780c-9381-4150-8c89-fc9fcaeed910">1.8</a>) </li>
<li>Prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> (<a href="#i4i_section_id_8ab32f0f-eea7-4352-aaf3-afacf5e3cc43">1.9</a>) </li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul><li>Adults: the usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours) followed by a maintenance dose of 100 mg daily. In the management of more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (particularly chronic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the urinary tract), 100 mg every 12 hours is recommended. (<a href="#i4i_section_id_447e73d9-82af-4a49-b5e8-c8f41c9dff04">2.1</a>)</li></ul>
<ul><li>For children above eight years of age: The recommended dosage schedule for children weighing 45 kg or less is 4.4 mg/kg of body weight divided into two doses on the first day of treatment, followed by 2.2 mg/kg of body weight given as a single daily dose or divided into two doses on subsequent days. For more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> up to 4.4 mg/kg of body weight may be used. For children over 45 kg, the usual adult dose should be used. (<a href="#i4i_section_id_7270cc66-0e4b-45c5-b94b-d29b2b71a263">2.1</a>)</li></ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 100 mg, 150 mg, and 200 mg (<a href="#i4i_dosage_form_strength_id_70d7d362-fd29-4f5f-8ff8-19122221c6ab">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Doxycycline is contraindicated in persons who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the tetracyclines. (<a href="#i4i_contraindications_id_81058a48-85ee-4af7-b9ae-fde6e032afad">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>The use of drugs of the tetracycline-class during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). (<a href="#i4i_section_id_d9fdd7f1-f5d9-48f6-8f57-8911df3c0ed2">5.1</a>)</li>
<li>
<span class="Italics">Clostridium difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>: Evaluate patients if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs. (<a href="#i4i_section_id_5ca68520-ed17-49a2-b87e-470509a19b7c">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Limit sun exposure. (<a href="#i4i_section_id_ea7de176-e6e9-4a0c-a0a5-08276ed38933">5.3</a>)</li>
<li>Overgrowth of non-susceptible organisms, including fungi, may occur. Re-evaluate therapy if <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs. (<a href="#i4i_section_id_b760cafa-44a3-41ea-8ed7-6db3d2e52cc0">5.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Adverse reactions observed in patients receiving tetracyclines include <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>. (<a href="#i4i_adverse_effects_id_80c2c4ef-6854-482f-bdc5-9290796f2190">6</a>)<br><br> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Warner Chilcott at 1-800-521-8813 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage (<a href="#i4i_section_id_c1fc1d2b-8d10-4126-87d2-439b4176ceb3">7.1</a>)</li>
<li>Avoid coadministration of tetracyclines with penicillin (<a href="#i4i_section_id_2aec8cd4-f8c4-47ef-98f6-8b2de6ec2728">7.2</a>)</li>
<li>Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron-containing preparations (<a href="#i4i_section_id_ab29acd9-6512-47f1-812e-37ba57dea852">7.3</a>)</li>
<li>Concurrent use of tetracycline may render oral contraceptives less effective (<a href="#i4i_section_id_53368fb2-caab-4599-9c4c-7aa6b50d840b">7.4</a>)</li>
<li>Barbiturates, carbamazepine and phenytoin decrease the half-life of doxycycline (<a href="#i4i_section_id_ab6e7e75-79b5-4810-8ce7-08cbdcc859e6">7.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pregnancy Category D (<a href="#i4i_pregnancy_id_e93b1512-b976-4458-b367-ce887aa8e1e9">8.1</a>)</li>
<li>Tetracyclines are excreted in human milk; however, the extent of absorption of doxycycline in the breastfed infant is not known. Doxycycline use during nursing should be avoided if possible. (<a href="#i4i_nursing_mothers_id_68d0bce4-cc19-44d0-ba5b-a9df1ba1e254">8.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 7/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-2" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-2.1" class="toc">1.1 Rickettsial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></a></h2>
<h2><a href="#section-2.2" class="toc">1.2 Sexually transmitted <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></a></h2>
<h2><a href="#section-2.3" class="toc">1.3 <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span></a></h2>
<h2><a href="#section-2.4" class="toc">1.4 Specific <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span></a></h2>
<h2><a href="#section-2.5" class="toc">1.5 Ophthalmic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></a></h2>
<h2><a href="#section-2.6" class="toc">1.6 <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> including inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure)</a></h2>
<h2><a href="#section-2.7" class="toc">1.7 Alternative treatment for selected <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> when penicillin is contraindicated</a></h2>
<h2><a href="#section-2.8" class="toc">1.8 Adjunctive therapy for acute intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> and severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span></a></h2>
<h2><a href="#section-2.9" class="toc">1.9 Prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span></a></h2>
<h1><a href="#section-3" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-3.1" class="toc">2.1 Usual Dosage and Administration</a></h2>
<h2><a href="#section-3.2" class="toc">2.2 For prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> </a></h2>
<h2><a href="#section-3.3" class="toc">2.3 Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure)</a></h2>
<h2><a href="#section-3.4" class="toc">2.4 Sprinkling the tablet over applesauce</a></h2>
<h1><a href="#section-4" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-5" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-6" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">5.1 Tooth Development</a></h2>
<h2><a href="#section-6.2" class="toc">5.2 Clostridium difficile associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></a></h2>
<h2><a href="#section-6.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span></a></h2>
<h2><a href="#section-6.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">Superinfection</span></a></h2>
<h2><a href="#section-6.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">Benign Intracranial Hypertension</span></a></h2>
<h2><a href="#section-6.6" class="toc">5.6 Skeletal Development</a></h2>
<h2><a href="#section-6.7" class="toc">5.7 Antianabolic Action </a></h2>
<h2><a href="#section-6.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span></a></h2>
<h2><a href="#section-6.9" class="toc">5.9 Development of Drug-Resistant Bacteria </a></h2>
<h2><a href="#section-6.10" class="toc">5.10 Laboratory Monitoring for Long-Term Therapy </a></h2>
<h1><a href="#section-7" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">6.1 Clinical Trial Experience</a></h2>
<h2><a href="#section-7.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-8" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-8.1" class="toc">7.1 Anticoagulant Drugs</a></h2>
<h2><a href="#section-8.2" class="toc">7.2 Penicillin</a></h2>
<h2><a href="#section-8.3" class="toc">7.3 Antacids and Iron Preparations</a></h2>
<h2><a href="#section-8.4" class="toc">7.4 Oral Contraceptives</a></h2>
<h2><a href="#section-8.5" class="toc">7.5 Barbiturates and anti-epileptics</a></h2>
<h2><a href="#section-8.6" class="toc">7.6 Penthrane</a></h2>
<h2><a href="#section-8.7" class="toc">7.7 Drug/Laboratory Test Interactions</a></h2>
<h1><a href="#section-9" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-9.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-9.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-9.3" class="toc">8.4 Pediatric use</a></h2>
<h2><a href="#section-9.4" class="toc">8.5 Geriatric use</a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-12.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-13.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-15" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-16" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-17" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-17.1" class="toc">17.1 Instructions for Breaking the 150 mg DORYX Dual-Scored Tablet</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="i4i_antibiotic_statement_id_53a712b8-e225-40b2-8f29-744feba26bf7"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_4e681f01-9fb8-4998-84ac-97f2ec3f3f43"></a><a name="section-2"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORYX and other antibacterial drugs, DORYX should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p>Doxycycline is a tetracycline-class antimicrobial indicated in the following conditions or diseases:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2d63d51d-f189-4214-b1f2-1257cadf0dcd"></a><a name="section-2.1"></a><p></p>
<h2>1.1 Rickettsial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></h2>
<p class="First">Rocky Mountain spotted <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, typhus <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and the typhus group, Q <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, rickettsialpox, and tick <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fevers</span> caused by <span class="Italics">Rickettsiae</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d34328b3-fbab-4d15-be0f-c9ac5a0dd818"></a><a name="section-2.2"></a><p></p>
<h2>1.2 Sexually transmitted <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></h2>
<p class="First">Uncomplicated urethral, endocervical or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by <span class="Italics">Chlamydia trachomatis.</span><br>Nongonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> caused by <span class="Italics">Ureaplasma urealyticum</span>.<br>Lymphogranuloma venereum caused by <span class="Italics">Chlamydia trachomatis</span>.<br><span class="product-label-link" type="condition" conceptid="199726" conceptname="Granuloma inguinale">Granuloma inguinale</span> caused by <span class="Italics">Calymmatobacterium granulomatis</span>.<br>Uncomplicated <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> caused by <span class="Italics">Neisseria gonorrhoeae.</span><br><span class="product-label-link" type="condition" conceptid="138973" conceptname="Chancroid">Chancroid</span> caused by <span class="Italics">Haemophilus ducreyi</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_52b37ce9-5e74-477a-8364-8bf665b92ec5"></a><a name="section-2.3"></a><p></p>
<h2>1.3 <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> caused by <span class="Italics">Mycoplasma pneumoniae</span>.<br>Psittacosis (ornithosis) caused by <span class="Italics">Chlamydophila psittaci</span>.</p>
<p>Because many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.</p>
<p>Doxycycline is indicated for treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by the following microorganisms, when bacteriological testing indicates appropriate susceptibility to the drug:<br><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> caused by <span class="Italics">Haemophilus influenzae</span>.<br><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> caused by <span class="Italics">Klebsiella </span>species.<br><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory infections</span> caused by <span class="Italics">Streptococcus pneumoniae</span>.Â  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3fb6aa54-c16e-421f-99c8-e3a5e2122682"></a><a name="section-2.4"></a><p></p>
<h2>1.4 Specific <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="440637" conceptname="Relapsing fever">Relapsing fever</span> due to <span class="Italics">Borrelia recurrentis</span>.<br><span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">Plague</span> due to <span class="Italics">Yersinia pestis</span>.<br>Tularemia due to <span class="Italics">Francisella tularensis</span>.<br><span class="product-label-link" type="condition" conceptid="198677" conceptname="Cholera">Cholera</span> caused by <span class="Italics">Vibrio cholerae</span>.<br>Campylobacter fetus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by <span class="Italics">Campylobacter fetus</span>.<br><span class="product-label-link" type="condition" conceptid="441497" conceptname="Brucellosis">Brucellosis</span> due to <span class="Italics">Brucella </span>species (in conjunction with streptomycin).<br>Bartonellosis due to <span class="Italics">Bartonella bacilliformis</span>.</p>
<p>Because many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.</p>
<p>Doxycycline is indicated for treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by the following gram-negative microorganisms, when bacteriological testing indicates appropriate susceptibility to the drug:<br><span class="Italics">Escherichia coli</span><br><span class="Italics">Enterobacter aerogenes</span><br><span class="Italics">Shigella </span>species<br><span class="Italics">Acinetobacter </span>species<br><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infections</span> caused by <span class="Italics">Klebsiella</span> species.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_95f2a5bd-7a01-4bb3-aef6-31cdfbb00df8"></a><a name="section-2.5"></a><p></p>
<h2>1.5 Ophthalmic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></h2>
<p class="First">Trachoma caused by <span class="Italics">Chlamydia trachomatis</span>, although the infectious agent is not always eliminated as judged by immunofluorescence.<br>Inclusion <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> caused by <span class="Italics">Chlamydia trachomatis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_94d1dd7e-3c83-4cd0-8ff2-6911b2873a3a"></a><a name="section-2.6"></a><p></p>
<h2>1.6 <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> including inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure)</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> due to <span class="Italics">Bacillus anthracis</span>, including inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized <span class="Italics">Bacillus anthracis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9b2454b8-a5f3-4d33-b61b-de6705b3fa55"></a><a name="section-2.7"></a><p></p>
<h2>1.7 Alternative treatment for selected <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> when penicillin is contraindicated</h2>
<p class="First">When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>:<br><span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> caused by <span class="Italics">Treponema pallidum</span>.<br>Yaws caused by <span class="Italics">Treponema pertenue</span>.<br>Vincentâ€™s <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by <span class="Italics">Fusobacterium fusiforme.</span><br><span class="product-label-link" type="condition" conceptid="436020" conceptname="Actinomycotic infection">Actinomycosis</span> caused by <span class="Italics">Actinomyces israelii</span>.<br><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> caused by <span class="Italics">Clostridium </span>species.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f161780c-9381-4150-8c89-fc9fcaeed910"></a><a name="section-2.8"></a><p></p>
<h2>1.8 Adjunctive therapy for acute intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> and severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span></h2>
<p class="First">In acute intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span>, doxycycline may be a useful adjunct to amebicides. <br>In severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, doxycycline may be useful adjunctive therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8ab32f0f-eea7-4352-aaf3-afacf5e3cc43"></a><a name="section-2.9"></a><p></p>
<h2>1.9 Prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span></h2>
<p class="First">Doxycycline is indicated for the prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> due to <span class="Italics">Plasmodium falciparum</span> in short-term travelers (less than 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> [<span class="Italics">see</span><span class="Italics"> Dosage and Administration (<a href="#i4i_section_id_7270cc66-0e4b-45c5-b94b-d29b2b71a263">2.2</a>) and Patient Counseling Information (<a href="#i4i_info_patients_id_62dc5ea4-827a-47b4-9388-664875fcdaf1">17</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_646f9b6c-13f8-4a18-86fb-b066bcfd7c70"></a><a name="section-3"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_447e73d9-82af-4a49-b5e8-c8f41c9dff04"></a><a name="section-3.1"></a><p></p>
<h2>2.1 Usual Dosage and Administration</h2>
<p class="First">THE USUAL DOSAGE AND FREQUENCY OF ADMINISTRATION OF DOXYCYCLINE DIFFERS FROM THAT OF THE OTHER TETRACYCLINES. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS.</p>
<p>Adults: The usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours), followed by a maintenance dose of 100 mg daily. The maintenance dose may be administered as a single dose or as 50 mg every 12 hours. In the management of more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (particularly chronic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the urinary tract), 100 mg every 12 hours is recommended.</p>
<p>For pediatric patients above eight years of age: The recommended dosage schedule for children weighing 45 kg or less is 4.4 mg/kg of body weight divided into two doses on the first day of treatment, followed by 2.2 mg/kg of body weight given as a single daily dose or divided into two doses on subsequent days. For more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> up to 4.4 mg/kg of body weight may be used. For children over 45 kg, the usual adult dose should be used.</p>
<p>Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline-class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration [<span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_f501b612-3302-4db8-9244-9cca4c7b2bf7">6.1</a>)</span>].</p>
<p>If <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span> occurs, doxycycline may be given with food or milk [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_clinical_pharmacology_id_6194d2b6-717d-48d7-9216-795e178930ae">12</a>)</span>].</p>
<p>When used in <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>, therapy should be continued for 10 days.</p>
<p>Uncomplicated urethral, endocervical, or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by <span class="Italics">Chlamydia trachomatis</span>: 100 mg by mouth twice a day for 7 days.  As an alternate dosing regimen for uncomplicated urethral or endocervical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by <span class="Italics">Chlamydia trachomatis</span>, administer 200 mg by mouth once-a-day for 7 days.</p>
<p>Uncomplicated gonococcal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in adults (except anorectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in men): 100 mg, by mouth, twice-a-day for 7 days. As an alternate single visit dose, administer 300 mg stat followed in one hour by a second 300 mg dose.</p>
<p>Nongonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> (NGU) caused by <span class="Italics">U. urealyticum</span>: 100 mg by mouth twice-a-day for 7 days.</p>
<p><span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> â€“ early: Patients who are allergic to penicillin should be treated with doxycycline 100 mg by mouth twice-a-day for 2 weeks.</p>
<p><span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> of more than one yearâ€™s duration: Patients who are allergic to penicillin should be treated with doxycycline 100 mg by mouth twice-a-day for 4 weeks.</p>
<p>Acute epididymo-<span class="product-label-link" type="condition" conceptid="4171915" conceptname="Orchitis">orchitis</span> caused by <span class="Italics">C. trachomatis</span>: 100 mg, by mouth, twice-a-day for at least 10 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7270cc66-0e4b-45c5-b94b-d29b2b71a263"></a><a name="section-3.2"></a><p></p>
<h2>2.2 For prophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> </h2>
<p class="First">For adults, the recommended dose is 100 mg daily. For children over 8 years of age, the recommended dose is 2 mg/kg given once daily up to the adult dose. Prophylaxis should begin 1 or 2 days before travel to the malarious area. Prophylaxis should be continued daily during travel in the malarious area and for 4 weeks after the traveler leaves the malarious area.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cdc7b5f2-2e66-4616-9e0a-cf2ca6f6f9eb"></a><a name="section-3.3"></a><p></p>
<h2>2.3 Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure)</h2>
<p class="First">ADULTS: 100 mg, of doxycycline, by mouth, twice-a-day for 60 days. <br>CHILDREN: weighing less than 45 kg, 2.2 mg/kg of body weight, by mouth, twice-a-day for 60 days. Children weighing 45 kg or more should receive the adult dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_00a3e61c-2824-4302-8086-98cf8ebf7304"></a><a name="section-3.4"></a><p></p>
<h2>2.4 Sprinkling the tablet over applesauce</h2>
<p class="First">DORYX Tablets may also be administered by carefully breaking up the tablet and sprinkling the tablet contents (delayed-release pellets) on a spoonful of applesauce. The delayed-release pellets must not be crushed or damaged when breaking up the tablet. Any loss of pellets in the transfer would prevent using the dose. The applesauce/DORYX mixture should be swallowed immediately without chewing and may be followed by a glass of water if desired. The applesauce should not be hot, and it should be soft enough to be swallowed without chewing. In the event that a prepared dose of applesauce/DORYX Tablet cannot be taken immediately, the mixture should be discarded and not stored for later use.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_70d7d362-fd29-4f5f-8ff8-19122221c6ab"></a><a name="section-4"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">DORYX (doxycycline hyclate delayed-release tablets, USP), 100 mg are white, oval scored tablets containing yellow pellets and debossed with â€œD|1â€? on one face and plain on the other. Each tablet contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline.</p>
<p>DORYX (doxycycline hyclate delayed-release tablets, USP), 150 mg are white, rectangular dual-scored tablets containing yellow pellets and debossed with â€œD|D|Dâ€? on one face and dual-scored on the other. Each tablet contains specially coated pellets of doxycycline hyclate equivalent to 150 mg of doxycycline.</p>
<p>DORYXÂ  (doxycycline hyclate delayed-release tablets), 200 mg are white, oval scored tablets containing yellow pellets and debossed with â€œD|Dâ€? on one face and plain on the other. Each tablet contains specially coated pellets of doxycycline hyclate equivalent to 200 mg of doxycycline.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_81058a48-85ee-4af7-b9ae-fde6e032afad"></a><a name="section-5"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">The drug is contraindicated in persons who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the tetracyclines.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_90855c23-52bd-4268-9fa7-bdfe40887969"></a><a name="section-6"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d9fdd7f1-f5d9-48f6-8f57-8911df3c0ed2"></a><a name="section-6.1"></a><p></p>
<h2>5.1 Tooth Development</h2>
<p class="First">The use of drugs of the tetracycline-class during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drugs but it has been observed following repeated short-term courses. <span class="product-label-link" type="condition" conceptid="4131814" conceptname="Enamel hypoplasia">Enamel hypoplasia</span> has also been reported. Doxycycline should not be used in this age group, except for <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span>, including inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure), unless other drugs are not likely to be effective or are contraindicated. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5ca68520-ed17-49a2-b87e-470509a19b7c"></a><a name="section-6.2"></a><p></p>
<h2>5.2 Clostridium difficile associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></h2>
<p class="First"><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including DORYX Tablets, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibacterial use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ea7de176-e6e9-4a0c-a0a5-08276ed38933"></a><a name="section-6.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">skin erythema</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b760cafa-44a3-41ea-8ed7-6db3d2e52cc0"></a><a name="section-6.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">Superinfection</span></h2>
<p class="First">As with other antibacterial preparations, use of DORYX may result in overgrowth of non-susceptible organisms, including fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, the antibacterial should be discontinued and appropriate therapy instituted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_612864f0-527e-4e72-85f4-72281e5587a1"></a><a name="section-6.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">Benign Intracranial Hypertension</span></h2>
<p class="First">Bulging fontanels in infants and <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">benign intracranial hypertension</span> in adults have been reported in individuals receiving tetracyclines. These conditions disappeared when the drug was discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2755c37d-f2fc-4d46-bb59-f1e9ff95d0b8"></a><a name="section-6.6"></a><p></p>
<h2>5.6 Skeletal Development</h2>
<p class="First">All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every six hours. This reaction was shown to be reversible when the drug was discontinued.</p>
<p>Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity also has been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of the potential hazard to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_40e830c4-5ef0-4254-9f13-d8a36858330b"></a><a name="section-6.7"></a><p></p>
<h2>5.7 Antianabolic Action </h2>
<p class="First">The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_77f7ab52-8aba-419d-b357-37f54e3ed77e"></a><a name="section-6.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span></h2>
<p class="First">Doxycycline offers substantial but not complete suppression of the asexual blood stages of <span class="Italics">Plasmodium</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>.</p>
<p>Doxycycline does not suppress <span class="Italics">P. falciparumâ€™s </span>sexual blood stage gametocytes. Subjects completing this <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> regimen may still transmit the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to mosquitoes outside endemic areas. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_12d20959-2e4f-42a2-a7a7-735a2c94d9e6"></a><a name="section-6.9"></a><p></p>
<h2>5.9 Development of Drug-Resistant Bacteria </h2>
<p class="First">Prescribing DORYX in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c53676b9-63db-4670-8d82-68bebbc985e0"></a><a name="section-6.10"></a><p></p>
<h2>5.10 Laboratory Monitoring for Long-Term Therapy </h2>
<p class="First">In long-term therapy, periodic laboratory evaluation of organ systems, including hematopoietic, renal, and hepatic studies should be performed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_80c2c4ef-6854-482f-bdc5-9290796f2190"></a><a name="section-7"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f501b612-3302-4db8-9244-9cca4c7b2bf7"></a><a name="section-7.1"></a><p></p>
<h2>6.1 Clinical Trial Experience</h2>
<p class="First">The safety and efficacy of DORYX Tablets, 200 mg as a single daily dose was evaluated in a multicenter, randomized, double-blind, active-controlled study. DORYX Tablets, 200 mg was given orally once-a-day for 7 days and compared to doxycycline hyclate capsules 100 mg given orally twice daily for 7 days for the treatment of men and women with uncomplicated urogenital <span class="Italics">C. trachomatis </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Adverse events in the Safety Population were reported by 99 (40.2 %) subjects in the DORYX Tablets, 200 mg treatment group and 132 (53.2 %) subjects in the doxycycline hyclate capsules reference treatment group. Most AEs were mild in intensity. The most commonly reported adverse events in both treatment groups were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and bacterial <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, <a href="#id_d74a5549-4c61-4142-96af-80b296bbcf4f">Table 1</a>.</p>
<a name="id_d74a5549-4c61-4142-96af-80b296bbcf4f"></a><table border="single" width="532">
<caption><span>Table 1: Adverse Reactions Reported in Greater than or Equal to 2% of Subjects</span></caption>
<col width="11.8%">
<col width="42.9%">
<col width="45.3%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">DORYX Tablets, </span></p>
<p><span class="Bold">200 mg<br>N = 246</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><p class="First">Preferred Term</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">n (%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><p class="First">Subjects with any AE</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle">99 (40.2)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">Â </td>
<td class="Botrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Rrule" align="center" valign="middle">33 (13.4)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Rrule" align="center" valign="middle">20 (8.1)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Rrule" align="center" valign="middle">5 (2.0)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Rrule" align="center" valign="middle">8 (3.3)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="middle"><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal Pain Upper</span></td>
<td class="Botrule Rrule" align="center" valign="middle">5 (2.0)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="middle"> <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">Vaginitis Bacterial</span></td>
<td class="Botrule Rrule" align="center" valign="middle">8 (3.3)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="middle">Vulvovaginal Mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Botrule Rrule" align="center" valign="middle">5 (2.0)</td>
</tr>
</tbody>
</table>
<p>Because clinical trials are conducted under prescribed conditions, adverse reaction rates observed in the clinical trial may not always reflect the rates observed in practice.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4bd535a8-8cf7-49fc-a7e9-a695b2b8b077"></a><a name="section-7.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">Due to oral doxycyclineâ€™s virtually complete absorption, side effects to the lower bowel, particularly <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines: </p>
<p><span class="Italics">Gastrointestinal</span>: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, and inflammatory lesions (with monilial overgrowth) in the anogenital region. Hepatotoxicity has been reported. These reactions have been caused by both the oral and parenteral administration of tetracyclines. <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">Esophagitis</span> and <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulcerations</span> have been reported in patients receiving capsule and tablet forms of drugs in the tetracycline-class. Most of these patients took medications immediately before going to bed [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_447e73d9-82af-4a49-b5e8-c8f41c9dff04">2.1</a>)</span>].</p>
<p><span class="Italics">Skin</span>: Maculopapular and erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>,Â  and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> have been reported. <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> is discussed above [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_ea7de176-e6e9-4a0c-a0a5-08276ed38933">5.3</a>)</span>].</p>
<p><span class="Italics">Renal</span>: Rise in BUN has been reported and is apparently dose-related [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_40e830c4-5ef0-4254-9f13-d8a36858330b">5.7</a>)</span>].</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span></span>: <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="4101602" conceptname="Henoch-Schonlein purpura">anaphylactoid purpura</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, and exacerbation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
<p><span class="Italics">Blood</span>: <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> have been reported.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">Benign Intracranial Hypertension</span></span></p>
<p>Bulging fontanels in infants and <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">benign intracranial hypertension</span> in adults [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_612864f0-527e-4e72-85f4-72281e5587a1">5.5</a>)</span>].</p>
<p><span class="Italics">Thyroid Gland Changes</span>: When given over <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>, tetracyclines have been reported to produce brown-black microscopic discoloration of thyroid glands. No abnormalities of thyroid function are known to occur.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_0a835b6a-63c4-4461-b360-9cffce65b1f2"></a><a name="section-8"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c1fc1d2b-8d10-4126-87d2-439b4176ceb3"></a><a name="section-8.1"></a><p></p>
<h2>7.1 Anticoagulant Drugs</h2>
<p class="First">Because tetracyclines have been shown to depress plasma <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2aec8cd4-f8c4-47ef-98f6-8b2de6ec2728"></a><a name="section-8.2"></a><p></p>
<h2>7.2 Penicillin</h2>
<p class="First">Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ab29acd9-6512-47f1-812e-37ba57dea852"></a><a name="section-8.3"></a><p></p>
<h2>7.3 Antacids and Iron Preparations</h2>
<p class="First">Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_53368fb2-caab-4599-9c4c-7aa6b50d840b"></a><a name="section-8.4"></a><p></p>
<h2>7.4 Oral Contraceptives</h2>
<p class="First">Concurrent use of tetracycline may render oral contraceptives less effective.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ab6e7e75-79b5-4810-8ce7-08cbdcc859e6"></a><a name="section-8.5"></a><p></p>
<h2>7.5 Barbiturates and anti-epileptics</h2>
<p class="First">Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d64909f9-5897-4f2d-b48d-e684ab06a8ea"></a><a name="section-8.6"></a><p></p>
<h2>7.6 Penthrane</h2>
<p class="First">The concurrent use of tetracycline and Penthrane<span class="Sup">Â®</span> (methoxyflurane) has been reported to result in fatal renal toxicity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8537fc80-02b2-4f64-bda2-bf4bd4f2f800"></a><a name="section-8.7"></a><p></p>
<h2>7.7 Drug/Laboratory Test Interactions</h2>
<p class="First">False elevations of urinary catecholamines may occur due to interference with the fluorescence test.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_58c34d18-5d5f-45c0-971c-878f8e9571b6"></a><a name="section-9"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_e93b1512-b976-4458-b367-ce887aa8e1e9"></a><a name="section-9.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Teratogenic Effects. Pregnancy Category D: </span></p>
<p>There are no adequate and well-controlled studies on the use of doxycycline in pregnant women. The vast majority of reported experience with doxycycline during human pregnancy is short-term, first trimester exposure. There are no human data available to assess the effects of long-term therapy of doxycycline in pregnant women such as that proposed for the treatment of <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> exposure. An expert review of published data on experiences with doxycycline use during pregnancy by TERIS - the Teratogen Information System - concluded that therapeutic doses during pregnancy are unlikely to pose a substantial teratogenic risk (the quantity and quality of data were assessed as limited to fair), but the data are insufficient to state that there is no risk.<span class="Sup">1</span></p>
<p>A case-control study (18,515 mothers of infants with congenital anomalies and 32,804 mothers of infants with no congenital anomalies) shows a weak but marginally statistically significant association with total malformations and use of doxycycline anytime during pregnancy. Sixty-three (0.19%) of the controls and 56 (0.30%) of the cases were treated with doxycycline. This association was not seen when the analysis was confined to maternal treatment during the period of organogenesis (that is, in the second and third months of gestation), with the exception of a marginal relationship with <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defect</span> based on only two-exposed cases.<span class="Sup">2</span></p>
<p>A small prospective study of 81 pregnancies describes 43 pregnant women treated for 10 days with doxycycline during early first trimester. All mothers reported their exposed infants were normal at 1 year of age.<span class="Sup">3</span></p>
<p>Nonteratogenic effects: [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_d9fdd7f1-f5d9-48f6-8f57-8911df3c0ed2">5.1</a>, <a href="#i4i_section_id_2755c37d-f2fc-4d46-bb59-f1e9ff95d0b8">5.6</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_68d0bce4-cc19-44d0-ba5b-a9df1ba1e254"></a><a name="section-9.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Tetracyclines are excreted in human milk, however, the extent of absorption of tetracyclines including doxycycline, by the breastfed infant is not known. Short-term use by lactating women is not necessarily contraindicated. The effects of prolonged exposure to doxycycline in breast milk are unknown<span class="Sup">4</span>. Because of the potential for serious adverse reactions in nursing infants from doxycycline, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_d9fdd7f1-f5d9-48f6-8f57-8911df3c0ed2">5.1</a>, <a href="#i4i_section_id_2755c37d-f2fc-4d46-bb59-f1e9ff95d0b8">5.6</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_81d7f420-34a7-45f4-8237-a89df163e493"></a><a name="section-9.3"></a><p></p>
<h2>8.4 Pediatric use</h2>
<p class="First">Because of the effects of drugs of the tetracycline-class on tooth development and growth, DORYX should not be used in pediatric patients to the age of 8 years, unless the potential benefits are expected to outweigh the risks such as for <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span>, or when other drugs are not likely to be effective or are contraindicated [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_d9fdd7f1-f5d9-48f6-8f57-8911df3c0ed2">5.1</a>, <a href="#i4i_section_id_2755c37d-f2fc-4d46-bb59-f1e9ff95d0b8">5.6</a>) and Dosage and Administration (<a href="#i4i_section_id_447e73d9-82af-4a49-b5e8-c8f41c9dff04">2.1</a>, <a href="#i4i_section_id_cdc7b5f2-2e66-4616-9e0a-cf2ca6f6f9eb">2.3</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_a603b70a-854c-4de5-9435-533720a606b8"></a><a name="section-9.4"></a><p></p>
<h2>8.5 Geriatric use</h2>
<p class="First">Clinical studies of DORYX did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</p>
<p>DORYX 100 mg tablets contain 6 mg (0.261 mEq) of sodium.<br>DORYX 150 mg tablets contain 9 mg (0.392 mEq) of sodium.<br>DORYX 200 mg tablets contain 12 mg (0.522 mEq) of sodium.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_400f3e55-1481-4f98-9a38-38b011d110a3"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdosage.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_8eb553d9-503f-4f7a-ae6c-3fc505cfab22"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">DORYX (doxycycline hyclate delayed-release tablets), for oral administration, contain specially coated pellets of doxycycline hyclate, a broad-spectrum antibacterial synthetically derived from oxytetracycline, in a delayed-release formulation for oral administration.<br></p>
<p>The structural formula for doxycycline hyclate is:</p>
<p><img alt="Doxycycline Hyclate structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-01.jpg"></p>
<p>with a molecular formula of C<span class="Sub">22</span>H<span class="Sub">24</span>N<span class="Sub">2</span>O<span class="Sub">8</span>, HCl, Â½ C<span class="Sub">2</span>H<span class="Sub">6</span>O, Â½ H<span class="Sub">2</span>O and a molecular weight of 512.9. The chemical designation for doxycycline hyclate is [4S(4aR,5S,5aR,6R,12aS)]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-deoxonapthtacene-2-carboxamide monohydrochloride, compound with ethyl alcohol (2:1), monohydrate. Doxycycline hyclate is a yellow crystalline powder soluble in water and in solutions of alkali hydroxides and carbonates. Doxycycline has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form. Inactive ingredients in the tablet formulation are: lactose monohydrate; microcrystalline cellulose; sodium lauryl sulfate; sodium chloride; talc; anhydrous lactose; corn starch; crospovidone; magnesium stearate; cellulosic polymer coating.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_6194d2b6-717d-48d7-9216-795e178930ae"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_6a38f252-ef27-4b46-b24b-39f0d27a53ff"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Doxycycline is an antimicrobial drug [<span class="Italics">see Microbiology (<a href="#i4i_section_id_d86d16a1-1c24-41b7-88b4-6e7593a2b262">12.4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_55fd8584-54dc-4fcd-ad8d-ce15a200fb11"></a><a name="section-12.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Doxycycline is virtually completely absorbed after oral administration. Following single and multiple-dose administration of DORYX Tablets, 200 mg to adult volunteers, average peak plasma doxycycline concentration (C<span class="Sub">max</span>) was 4.6 mcg/mL and 6.3 mcg/mL, respectively with median t<span class="Sub">max</span> of 3 hours; the corresponding mean plasma concentration values 24 hours after single and multiple doses were 1.5 mcg/mL and 2.3 mcg/mL, respectively. The mean C<span class="Sub">max</span> and AUC <span class="Sub">0-âˆž</span> of doxycycline are 24% and 13% lower, respectively, following single dose administration of DORYX Tablets, 100 mg with a high fat meal (including milk) compared to fasted conditions. The mean C<span class="Sub">max </span>of doxycycline is 19% lower and the AUC <span class="Sub">0-âˆž </span>is unchanged following single dose administration of DORYX Tablets, 150 mg with a high fat meal (including milk) compared to fasted conditions. The clinical significance of these decreases is unknown. Doxycycline bioavailability from DORYX Tablets, 200 mg was not affected by food, but the incidence of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> was higher in fasted subjects. The 200 mg tablets may be administered without regard to meals.</p>
<p>When DORYX Tablets are sprinkled over applesauce and taken with or without water, the extent of doxycycline absorption is unchanged, but the rate of absorption is increased slightly.</p>
<p>Tetracyclines are concentrated in bile by the liver and excreted in the urine and feces at high concentrations and in a biologically active form. Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with a creatinine clearance of about 75 mL/min. This percentage may <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> as low as 1-5%/72 hours in individuals with a creatinine clearance below 10 mL/min. </p>
<p>Studies have shown no significant difference in the serum half-life of doxycycline (range 18 to 22 hours) in individuals with normal and severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Hemodialysis does not alter the serum half-life.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d86d16a1-1c24-41b7-88b4-6e7593a2b262"></a><a name="section-12.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First">Mechanism of Action</p>
<p>Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Doxycycline has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria. Cross-resistance between tetracyclines is common.</p>
<p>Doxycycline has been shown to be active against most isolates of the following bacteria, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold">INDICATIONS AND USAGE</span> section of the package insert for DORYX.</p>
<p><span class="Bold">Gram-Negative Bacteria</span><br><span class="Italics">Acinetobacter</span> species<span class="Italics"><br>Bartonella bacilliformis</span><br><span class="Italics">Brucella </span>species<br><span class="Italics">Calymmatobacterium granulomatis</span><span class="Italics"><br>Campylobacter fetus</span><br><span class="Italics">Enterobacter aerogenes</span><br><span class="Italics">Escherichia coli</span><br><span class="Italics">Francisella tularensis</span><br><span class="Italics">Haemophilus ducreyi</span><br><span class="Italics">Haemophilus influenzae</span><br><span class="Italics">Klebsiella </span>species<br><span class="Italics">Neisseria gonorrhoeae</span><br><span class="Italics">Shigella </span>species<br><span class="Italics">Vibrio Cholerae</span><br><span class="Italics">Yersinia pestis</span></p>
<p><span class="Bold">Gram-Positive Bacteria</span><br><span class="Italics">Bacillus anthracis</span><br><span class="Italics">Streptococcus pneumoniae</span></p>
<p><span class="Bold">Anerobic Bacteria</span><br><span class="Italics">Clostridium</span> species<br><span class="Italics">Fusobacterium fusiforme</span><br><span class="Italics">Propionibacterium <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acnes</span></span></p>
<p><span class="Bold">Other Bacteria</span><br><span class="Italics">Actinomyces </span>species     <br><span class="Italics">Borrelia recurrentis</span><br><span class="Italics">Chlamydophila psittaci</span><br><span class="Italics">Chlamydia trachomatis</span><br><span class="Italics">Mycoplasma pneumoniae</span><br>     Rickettsiae     <br><span class="Italics">Treponema pallidum</span><br><span class="Italics">Treponema pertenue</span><br><span class="Italics">Ureaplasma urealyticum </span></p>
<p><span class="Bold">Parasites</span><br><span class="Italics">Balantidium coli</span><br><span class="Italics">Entamoeba </span>species<br><span class="Italics">Plasmodium falciparum</span>*    </p>
<p>*Doxycycline has been found to be active against the asexual erythrocytic forms of <span class="Italics">Plasmodium falciparum </span>but not against the gametocytes of <span class="Italics">P. falciparum. </span>The precise mechanism of action of the drug is not known.</p>
<p><span class="Bold">Susceptibility Test Methods </span></p>
<p>When available, the clinical microbiology laboratory should provide the results of <span class="Italics">in vitro</span> susceptibility test results for antimicrobial drugs used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial.</p>
<p><span class="Bold">Dilution Techniques</span></p>
<p>Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method (broth and/or agar)<span class="Sup">5,6,8</span>. The MIC values should be interpreted according to the criteria provided in <a href="#id_640996a0-18e9-4ff0-9059-b862f3bfe017">Table 2</a>.</p>
<p><span class="Bold">Diffusion Techniques</span></p>
<p>Quantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. Zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standard test method<span class="Sup">5,7,8</span>. This procedure uses paper disks impregnated with 30 mcg doxycycline to test the susceptibility of bacteria to doxycycline. The disk diffusion interpretive criteria are provided in <a href="#id_640996a0-18e9-4ff0-9059-b862f3bfe017">Table 2</a>.</p>
<p><span class="Bold">Anaerobic Techniques</span></p>
<p>For anaerobic bacteria, the susceptibility to doxycycline can be determined by a standardized test method<span class="Sup">9</span>. The MIC values obtained should be interpreted according to the criteria provided in <a href="#id_640996a0-18e9-4ff0-9059-b862f3bfe017">Table 2</a>.</p>
<a name="id_640996a0-18e9-4ff0-9059-b862f3bfe017"></a><table border="none" width="610">
<caption><span>Table 2: Susceptibility Test Interpretive Criteria for Doxycycline and Tetracycline</span></caption>
<col width="23.4%">
<col width="10.2%">
<col width="9.3%">
<col width="9.5%">
<col width="9.3%">
<col width="9.3%">
<col width="7.2%">
<col width="7.2%">
<col width="8.2%">
<col width="6.2%">
<tfoot><tr><td colspan="10" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Organisms susceptible to tetracycline are also considered susceptible to doxycycline. However, some organisms that are intermediate or resistant to tetracycline may be susceptible to doxycycline.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">â€ </a></dt>
<dd>The current absence of resistance isolates precludes defining any results other than â€œSusceptibleâ€?. If isolates yielding MIC results other than susceptible, they should be submitted to a reference laboratory for further testing.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€¡</a></dt>
<dd>Gonococci with 30 mcg tetracycline disk zone diameters of less than 19 mm usually indicate a plasmid-mediated tetracycline resistant <span class="Italics">Neisseria gonorrhoeae</span> isolate. Resistance in these <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> should be confirmed by a dilution test (MIC greater than or equal to 16 mcg/mL).</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First Toprule">
<td class="Botrule Rrule" align="left" valign="top">
<span class="Bold">Bacteria</span><span class="Bold"><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span>
</td>
<td class="Botrule Rrule" align="center" colspan="3" valign="middle">Â          <p class="First"><span class="Bold">Minimal Inhibitory</span></p>
<p><span class="Bold">Concentration </span></p>
<p><span class="Bold">(mcg/mL)</span></p>Â         </td>
<td class="Botrule Rrule" align="center" colspan="3" valign="middle">Â              <p class="First"><span class="Bold">Zone </span></p>
<p><span class="Bold">Diameter </span></p>
<p><span class="Bold">(mm)</span></p>Â         </td>
<td class="Botrule" align="center" colspan="3" valign="middle">
<p class="First"><span class="Bold">Agar </span></p>
<p><span class="Bold">Dilution</span></p>
<p><span class="Bold">(mcg/mL)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">         S        </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">         I        </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">         R        </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">         S        </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">         I        </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">         R        </span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">S</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">I</span></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">R</span></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Italics">Acinetobacter spp.</span></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"> Â Â Â Â Doxycycline</td>
<td class="Rrule" align="center" valign="middle">â‰¤4</td>
<td class="Rrule" align="center" valign="middle">8</td>
<td class="Rrule" align="center" valign="middle">â‰¥16</td>
<td class="Rrule" align="center" valign="middle">â‰¥13</td>
<td class="Rrule" align="center" valign="middle">10-12</td>
<td class="Rrule" align="center" valign="middle">â‰¤9</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¤4</td>
<td class="Botrule Rrule" align="center" valign="middle">8</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¥16</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¥15</td>
<td class="Botrule Rrule" align="center" valign="middle">12-14</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¤11</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule" align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">Anaerobes</td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¤4</td>
<td class="Botrule Rrule" align="center" valign="middle">8</td>
<td class="Botrule" align="center" valign="middle">â‰¥16</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">
<span class="Italics">Bacillus anthracis</span><a href="#footnote-1" class="Sup">*</a><a name="footnote-reference-2" href="#footnote-2" class="Sup">â€ </a>
</td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"> Â Â Â Â Doxycycline</td>
<td class="Rrule" align="center" valign="middle">â‰¤1</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¤1</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule" align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">
<span class="Italics">Brucella </span>species<a href="#footnote-1" class="Sup">*</a><a href="#footnote-2" class="Sup">â€ </a>
</td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"> Â Â Â Â Doxycycline</td>
<td class="Rrule" align="center" valign="middle">â‰¤1</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¤1</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule" align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Italics">Enterobacteriaceae</span></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"> Â Â Â Â Doxycycline</td>
<td class="Rrule" align="center" valign="middle">â‰¤4</td>
<td class="Rrule" align="center" valign="middle">8</td>
<td class="Rrule" align="center" valign="middle">â‰¥16</td>
<td class="Rrule" align="center" valign="middle">â‰¥14</td>
<td class="Rrule" align="center" valign="middle">11-13</td>
<td class="Rrule" align="center" valign="middle">â‰¤10</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¤4</td>
<td class="Botrule Rrule" align="center" valign="middle">8</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¥16</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¥15</td>
<td class="Botrule Rrule" align="center" valign="middle">12-14</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¤11</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule" align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">
<span class="Italics">Franciscella tularensis</span><a href="#footnote-1" class="Sup">*</a><a href="#footnote-2" class="Sup">â€ </a>
</td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"> Â Â Â Â Doxycycline</td>
<td class="Rrule" align="center" valign="middle">â‰¤4</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¤4</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule" align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Italics">Haemophilus influenzae</span></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¤2</td>
<td class="Botrule Rrule" align="center" valign="middle">4</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¥8</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¥29</td>
<td class="Botrule Rrule" align="center" valign="middle">26-28</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¤25</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule" align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Italics">Mycoplasma pneumoniae</span></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¤2</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule" align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">
<span class="Italics">Nocardiae</span> and other aerobic <span class="Italics">Actinomyces</span> species<a href="#footnote-1" class="Sup">*</a><a href="#footnote-2" class="Sup">â€ </a>
</td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Doxycycline</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¤1</td>
<td class="Botrule Rrule" align="center" valign="middle">2-4</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¥8</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">
<span class="Italics">Neisseria gonorrhoeae</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">â€¡</a>
</td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¥38</td>
<td class="Botrule Rrule" align="center" valign="middle">31-37</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¤30</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¤0.25</td>
<td class="Botrule Rrule" align="center" valign="middle">0.5-1</td>
<td class="Botrule" align="center" valign="middle">â‰¥2</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Italics">Streptococcus pneumoniae</span></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¤2</td>
<td class="Botrule Rrule" align="center" valign="middle">4</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¥8</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¥23</td>
<td class="Botrule Rrule" align="center" valign="middle">19-22</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¤18</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule" align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Italics">Vibrio cholerae</span></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"> Â Â Â Â Doxycycline</td>
<td class="Rrule" align="center" valign="middle">â‰¤4</td>
<td class="Rrule" align="center" valign="middle">8</td>
<td class="Rrule" align="center" valign="middle">â‰¥16</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¤4</td>
<td class="Botrule Rrule" align="center" valign="middle">8</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¥16</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule" align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Italics">Yersinia pestis</span></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"> Â Â Â Â Doxycycline</td>
<td class="Rrule" align="center" valign="middle">â‰¤4</td>
<td class="Rrule" align="center" valign="middle">8</td>
<td class="Rrule" align="center" valign="middle">â‰¥16</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¤4</td>
<td class="Botrule Rrule" align="center" valign="middle">8</td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¥16</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule" align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Italics">Ureaplasma urealyticum</span></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr class="Botrule Last">
<td class="Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">â‰¤1</td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle">â‰¥2</td>
</tr>
</tbody>
</table>
<p>A report of <span class="Italics">Susceptible </span>(S) indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site necessary to inhibit growth of the pathogen. A report of <span class="Italics">Intermediate</span> (I) indicates that the result should be considered equivocal, and, if the bacteria is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of <span class="Italics">Resistant</span> (R) indicates that the antimicrobial is not likely to be inhibited growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site; other therapy should be selected.</p>
<p><span class="Bold">Quality Control</span></p>
<p>Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test<span class="Sup">5,6,7,8,9,10,11</span>. Standard doxycycline and tetracycline powders should provide the following range of MIC values noted in <a href="#id_fb536aa5-0b80-4888-a1e6-d1b8ed22f523">Table 3</a>. For the diffusion technique using the 30 mcg doxycycline disk the criteria noted in <a href="#id_fb536aa5-0b80-4888-a1e6-d1b8ed22f523">Table 3</a> should be achieved.</p>
<a name="id_fb536aa5-0b80-4888-a1e6-d1b8ed22f523"></a><table border="none" width="624">
<caption><span>Table 3: Acceptable Quality Control Ranges for Susceptibility Testing  for Doxycycline and Tetracycline </span></caption>
<col width="35.7%">
<col width="25.0%">
<col width="23.7%">
<col width="15.5%">
<tbody class="Headless">
<tr class="First Toprule">
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strain</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Minimal <br>Inhibitory<br>Concentration <br>(mcg/mL)</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">Zone <br>Diameter <br>(mm)</span></p></td>
<td class="Botrule" align="center" valign="middle"><p class="First"><span class="Bold">Agar <br>Dilution <br>(mcg/mL)</span></p></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Italics">Enterococcus faecalis ATCC 29212</span></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"> Â Â Â Â Doxycycline</td>
<td class="Rrule" align="center" valign="middle">2 - 8</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">8 - 32</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule" align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Italics">Escherichia coli ATCC 25922</span></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"> Â Â Â Â Doxycycline</td>
<td class="Rrule" align="center" valign="middle">0.5 - 2</td>
<td class="Rrule" align="center" valign="middle">18 - 24</td>
<td align="center" valign="middle">- </td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">0.5 - 2</td>
<td class="Botrule Rrule" align="center" valign="middle">18 - 25</td>
<td class="Botrule" align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">
<span class="Italics">Haemophilus influenzae </span>ATCC 49247</td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">4 - 32</td>
<td class="Botrule Rrule" align="center" valign="middle">14 - 22</td>
<td class="Botrule" align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">
<span class="Italics">Neisseria gonorrhoeae </span>ATCC 49226</td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">30 - 42</td>
<td class="Botrule" align="center" valign="middle">0.25 - 1</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="middle"><span class="Italics">Staphylococcus aureus ATCC 25923</span></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"> Â Â Â Â Doxycycline</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">23 - 29</td>
<td align="center" valign="middle">- </td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">24 - 30</td>
<td class="Botrule" align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Italics">Staphylococcus aureus ATCC 29213</span></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"> Â Â Â Â Doxycycline</td>
<td class="Rrule" align="center" valign="middle">0.12 - 0.5</td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">0.12 - 1</td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"><span class="Italics"><span class="Italics">Staphylococcus</span> pneumoniae ATCC 49619  </span></td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top"> Â Â Â Â Doxycycline</td>
<td class="Rrule" align="center" valign="middle">0.015 - 0.12</td>
<td class="Rrule" align="center" valign="middle">25 - 34</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">0.06 - 0.5</td>
<td class="Botrule Rrule" align="center" valign="middle">27 - 31</td>
<td class="Botrule" align="center" valign="middle">-</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">
<span class="Italics">Bacteroides fragilis </span>ATCC 25285</td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule" align="center" valign="middle">0.125 - 0.5</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">
<span class="Italics">Bacteroides thetaiotaomicron </span>ATCC 29741</td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">    Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule Rrule" align="center" valign="middle">-</td>
<td class="Botrule" align="center" valign="middle">8 - 32</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">
<span class="Italics">Mycoplasma pneumoniae </span>ATCC 29342</td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Botrule Rrule" align="center" valign="middle">0.06 - 0.5</td>
<td class="Botrule Rrule" align="center" valign="middle">- </td>
<td class="Botrule" align="center" valign="middle">0.06 - 0.5</td>
</tr>
<tr>
<td class="Rrule" align="left" valign="top">
<span class="Italics">Ureaplasma urealyticum </span>ATCC 33175</td>
<td class="Rrule" align="center" valign="middle"></td>
<td class="Rrule" align="center" valign="middle"></td>
<td align="center" valign="middle"></td>
</tr>
<tr class="Botrule Last">
<td class="Rrule" align="left" valign="top"> Â Â Â Â Tetracycline</td>
<td class="Rrule" align="center" valign="middle">-</td>
<td class="Rrule" align="center" valign="middle">- </td>
<td class="Botrule" align="center" valign="middle">â‰¥8</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_e075dbcd-941a-468d-8870-28546ff7fa5c"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_f4ba546f-d167-401a-9d53-7b13615c3079"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term studies in animals to evaluate carcinogenic potential of doxycycline have not been conducted. However, there has been evidence of oncogenic activity in rats in studies with the related antibiotics, oxytetracycline (adrenal and pituitary tumors) and minocycline (<span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">thyroid tumors</span>). Likewise, although mutagenicity studies of doxycycline have not been conducted, positive results in <span class="Italics">in vitro</span> mammalian cell assays have been reported for related antibacterials (tetracycline, oxytetracycline).</p>
<p>Doxycycline administered orally at dosage levels as high as 250 mg/kg/day had no apparent effect on the fertility of female rats. Effect on male fertility has not been studied.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_a43770ea-1c95-40bd-8df8-6eecca18b468"></a><a name="section-13.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">Hyperpigmentation of the thyroid has been produced by members of the tetracycline-class in the following species: in rats by oxytetracycline, doxycycline, tetracycline PO<span class="Sub">4</span>, and methacycline; in minipigs by doxycycline, minocycline, tetracycline PO<span class="Sub">4</span>, and methacycline; in dogs by doxycycline and minocycline; in monkeys by minocycline.</p>
<p>Minocycline, tetracycline PO<span class="Sub">4</span>, methacycline, doxycycline, tetracycline base, oxytetracycline HCl, and tetracycline HCl, were goitrogenic in rats fed a low iodine diet. This goitrogenic effect was accompanied by high radioactive iodine uptake. Administration of minocycline also produced a large <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span> with high radioiodine uptake in rats fed a relatively high iodine diet.</p>
<p>Treatment of various animal species with this class of drugs has also resulted in the induction of <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">thyroid hyperplasia</span> in the following: in rats and dogs (minocycline); in chickens (chlortetracycline); and in rats and mice (oxytetracycline). Adrenal gland <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> has been observed in goats and rats treated with oxytetracycline. </p>
<p>Results of animal studies indicate that tetracyclines cross the placenta and are found in fetal tissues.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_3f225a89-87b7-47d3-92a6-6aee88ac5377"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">This was a randomized, double-blind, active-controlled, multicenter trial which enrolled 495 subjects, between 19 to 45 years of age with a confirmed diagnosis of urogenital <span class="Italics">C. trachomatis </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> less than 14 days prior to enrollment, or partner(s) of a subject with a known positive test for urogenital <span class="Italics">C. trachomatis </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>The primary purpose of this study was to evaluate the efficacy and safety of DORYX Tablets, 200 mg once daily versus doxycycline hyclate capsules, 100 mg twice daily for seven days for the treatment of uncomplicated urogenital <span class="Italics">C. trachomatis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. The primary efficacy objective was to demonstrate non-inferiority of the DORYX Tablets, 200 mg once daily treatment regimen versus the doxycycline 100 mg twice daily treatment regimen for the indication using a negative nucleic acid amplification test (NAAT) at the test of cure visit (day 28) in the mITT population (subjects who were positive at baseline and took at least one day of study drug). </p>
<a name="id_211e7e27-57b6-412e-ad9e-1a0c349cce32"></a><table border="single" width="464">
<caption><span>Table 4: Primary Efficacy Outcome â€“ Microbiological Cure of C. trachomatis at Day 28</span></caption>
<col width="4.3%">
<col width="45.8%">
<col width="17.5%">
<col width="18.5%">
<col width="13.9%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">mITT Population </span></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">DORYX Tablets, 200 mg once daily</span></p>
<span class="Bold">Cure Rate (%)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Doxycycline hyclate capsules, 100 mg twice daily</span></p>
<span class="Bold">Cure Rate (%)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Difference</span></p>
<span class="Bold">(%) </span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">N</td>
<td class="Botrule Rrule" align="center" valign="top">188</td>
<td class="Botrule Rrule" align="center" valign="top">190</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">Microbiological Cure, n (%)</td>
<td class="Botrule Rrule" align="center" valign="top">163 (86.7)</td>
<td class="Botrule Rrule" align="center" valign="top">171 (90.0)</td>
<td class="Botrule Rrule" align="center" valign="top">-3.3%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">95% Confidence Interval for Cure Rate </td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">-10.3, 3.7</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_3c88f663-3693-43dd-b4c6-1753808aac5e"></a><a name="section-15"></a><p></p>
<h1>15 REFERENCES</h1>
<ol>
<li>Friedman JM, Polifka JE. <span class="Italics">Teratogenic Effects of Drug</span>s. <span class="Italics">A Resource for Clinicians </span>(TERIS).Â  Baltimore, MD: The Johns Hopkins University Press: 2000: 149-195.</li>
<li>Cziezel AE and Rockenbauer M. Teratogenic study of doxycycline. <span class="Italics">Obstet Gynecol </span>1997; 89: 524-528.</li>
<li>Horne HW Jr. and Kundsin RB. The role of mycoplasma among 81 consecutive pregnancies: a prospective study. <span class="Italics">Int J Fertil </span>1980; 25: 315-317.</li>
<li>Hale T. <span class="Italics">Medications and Mothers Milk</span>. 9<span class="Sup">th</span> edition. Amarillo, TX: Pharmasoft Publishing 2000; 225-226.</li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing; Twenty-third Informational </span>Supplement, CLSI document M100-S23. CLSI document M100S23, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne Pennsylvania 19087, USA, 2013. </li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - Nonth Edition.</span> CLSI document M07-A9, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne Pennsylvania 19087, USA, 2012.</li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard â€“ Eleventh Edition</span>. CLSI document M02-A11, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne Pennsylvania 19087, USA, 2012. </li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline â€“ Second Edition </span>CLSI document M45-A2, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne Pennsylvania 19087, USA, 2010.</li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard â€“ Eighth Edition</span>.Â  CLSI document M11-A8, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne Pennsylvania 19087, USA, 2012.</li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard â€“ Second Edition</span>.Â  CLSI document M24-A2, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne Pennsylvania 19087, USA, 2011. </li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Antimicrobial Susceptibility Testing for Human Mycoplasmas; Approved Guideline</span>.Â  CLSI document M43-A, Clinical Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne Pennsylvania 19087, USA, 2011.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_0e5f0959-6749-48b2-94c7-747fbbd086b6"></a><a name="section-16"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">DORYX<span class="Sup">Â®</span> (doxycycline hyclate delayed-release tablets, USP), 100 mg are white, oval scored tablets containing yellow pellets and debossed with â€œD|1â€? on one face and plain on the other. Each tablet contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline.</p>
<p>Bottles of 100 tablets: <span class="Bold">N</span> 0430-0112-24</p>
<p>DORYX<span class="Sup">Â®</span> (doxycycline hyclate delayed-release tablets, USP), 150 mg are white, rectangular dual-scored tablets containing yellow pellets and debossed with â€œD|D|Dâ€? on one face and dual-scored on the other. Each tablet contains specially coated pellets of doxycycline hyclate equivalent to 150 mg of doxycycline.</p>
<p>Bottles of 60 tablets: <span class="Bold">N</span> 0430-0115-20</p>
<p>DORYX<span class="Sup">Â®</span> (doxycycline hyclate delayed-release tablets), 200 mg are white, oval scored tablets containing yellow pellets and debossed with â€œD|Dâ€? on one face and plain on the other. Each tablet contains specially coated pellets of doxycycline hyclate equivalent to 200 mg of doxycycline.</p>
<p>Bottles of 60 tablets Â Â Â  Â Â Â Â  Â Â Â Â  <span class="Bold">N</span> 0430-0114-20</p>
<p>Store at 20 - 25Â° C (68 - 77Â° F); excursions permitted to 15 â€“ 30Â° C (59 â€“ 86Â° F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container (USP).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_62dc5ea4-827a-47b4-9388-664875fcdaf1"></a><a name="section-17"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients taking doxycycline for <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> prophylaxis should be advised:</p>
<ul>
<li>that no present-day antimalarial agent, including doxycycline, guarantees protection against <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>.</li>
<li>to avoid being bitten by mosquitoes by using personal protective measures that help avoid contact with mosquitoes, especially from dusk to dawn (for example, staying in well-screened areas, using mosquito nets, covering the body with clothing, and using an effective insect repellent).</li>
<li>that doxycycline prophylaxis:<ul>
<li>should begin 1 to 2 days before travel to the malarious area,</li>
<li>should be continued daily while in the malarious area and after leaving the malarious area,</li>
<li>should be continued for 4 further weeks to avoid development of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> after returning from an endemic area,</li>
<li>should not exceed 4 months.</li>
</ul>
</li>
</ul>
<p>All patients taking doxycycline should be advised:</p>
<ul>
<li>to avoid excessive sunlight or artificial ultraviolet light while receiving doxycycline and to discontinue therapy if <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> (for example, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span>, etc.) occurs. Sunscreen or sunblock should be considered [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_ea7de176-e6e9-4a0c-a0a5-08276ed38933">5.3</a>)</span>].</li>
<li>to drink fluids liberally along with doxycycline to reduce the risk of esophageal irritation and ulceration [<span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_f501b612-3302-4db8-9244-9cca4c7b2bf7">6.1</a>)</span>].</li>
<li>that the absorption of tetracyclines is reduced when taken with foods, especially those that contain calcium. However, the absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk [<span class="Italics">see Drug Interactions (<a href="#i4i_section_id_ab29acd9-6512-47f1-812e-37ba57dea852">7.3</a>)</span>].</li>
<li>that the absorption of tetracyclines is reduced when taken with antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron-containing preparations [<span class="Italics">see Drug Interactions (<a href="#i4i_section_id_ab29acd9-6512-47f1-812e-37ba57dea852">7.3</a>)</span>].</li>
<li>that the use of doxycycline might increase the incidence of <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>.</li>
</ul>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibacterials which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of antibacterial. If this occurs, patients should contact their physician as soon as possible.</p>
<p>Patients should be counseled that antibacterial drugs including DORYX should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (for example, the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When DORYX is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by DORYX or other antibacterial drugs in the future.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_29b75b68-e270-4a63-a73e-3325eb3de8f5"></a><a name="section-17.1"></a><p></p>
<h2>17.1 Instructions for Breaking the 150 mg DORYX Dual-Scored Tablet</h2>
<p class="First">The tablet is marked with separation lines (<span class="Bold">score lines</span>) and may be broken at these score lines to provide any of the following doses.</p>
<ul><li>150 mg treatment (the entire tablet is taken)</li></ul>
<a name="id_04d4808c-5c20-42ef-b484-1638767fd511"></a><table width="664.000">
<col width="47.9%">
<col width="52.1%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule" align="center" valign="middle"><img alt="top view and side view of 150 mg tablet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-02.jpg"></td>
<td class="Botrule" align="center" valign="middle"><img alt="full tablet side view with thumbs and index fingers" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-03.jpg"></td>
</tr></tbody>
</table>
<ul><li>100 mg treatment (two thirds of the tablet or two 50 mg tablet segments are taken)</li></ul>
<a name="id_e08006bb-ee2c-428e-83bd-20e6ed08dbc0"></a><table width="703.000">
<col width="49.9%">
<col width="50.1%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule" align="center" valign="middle"><img alt="top view and side view of 100 mg tablet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-04.jpg"></td>
<td class="Botrule" align="center" valign="middle"><img alt="two thirds tablet side view with thumbs and index fingers" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-05.jpg"></td>
</tr></tbody>
</table>
<ul><li>50 mg treatment (one third of the tablet is taken)</li></ul>
<a name="id_a043b9af-64af-481f-bbe9-86a2062d82c9"></a><table width="670.000">
<col width="47.5%">
<col width="52.5%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule" align="center" valign="top"><img alt="top view and side view of 50 mg tablet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-06.jpg"></td>
<td class="Botrule" align="center" valign="top"><img alt="one third tablet side view with thumb and index finger" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-07.jpg"></td>
</tr></tbody>
</table>
<p>To break the tablet, the tablet is held between the thumbs and index fingers close to the appropriate score line. Then, with the score line facing the patient, enough pressure is applied to snap the tablet segments apart (segments that do not break along the score line should not be used). </p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_e681e552-8152-40fc-906e-00dedb981d66"></a><a name="section-18"></a><p></p>
<h1>FDA-Approved Patient Labeling   </h1>
<p class="First"><span class="Bold">DORYX<span class="Sup">Â®</span> (doxycycline hyclate delayed-release tablets), 100 mg, 150 mg and 200 mg</span></p>
<p><span class="Bold">Instructions for Breaking the 150 mg DORYX Dual-Scored Tablet</span></p>
<p>Your doctor may find it necessary to adjust your dosage of DORYX<span class="Sup">Â®</span> to obtain the proper treatment response. The tablet is marked with separation lines (<span class="Bold">score lines</span>) and may be broken at these score lines to provide any of the following doses.</p>
<p>If your doctor prescribed:</p>
<ul><li>150 mg treatment (take the entire tablet)</li></ul>
<a name="id_8e00cd22-8b3d-4a4f-9f38-c3782024ec6f"></a><table width="664.000">
<col width="47.9%">
<col width="52.1%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule" align="center" valign="middle"><img alt="top view and side view of 150 tablet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-08.jpg"></td>
<td class="Botrule" align="center" valign="middle"><img alt="full tablet side view with thumbs and index fingers" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-09.jpg"></td>
</tr></tbody>
</table>
<ul><li>100 mg treatment (take two thirds of the tablet or two 50 mg tablet segments)</li></ul>
<a name="id_80516603-d912-4911-9154-43e23b8b92df"></a><table width="703.000">
<col width="49.9%">
<col width="50.1%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule" align="center" valign="middle"><img alt="top view and side view of 100 mg tablet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-10.jpg"></td>
<td class="Botrule" align="center" valign="middle"><img alt="two thirds tablet side view with thumbs and index fingers" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-11.jpg"></td>
</tr></tbody>
</table>
<ul><li>50 mg treatment (take one third of the tablet)</li></ul>
<a name="id_f59446bb-48a9-4780-b140-789a221abad2"></a><table width="670.000">
<col width="47.5%">
<col width="52.5%">
<tbody class="Headless"><tr class="First Last">
<td class="Botrule" align="center" valign="top"><img alt="top view and side view of 50 mg tablet" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-12.jpg"></td>
<td class="Botrule" align="center" valign="top"><img alt="one third tablet side view with thumb and index finger" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-13.jpg"></td>
</tr></tbody>
</table>
<p>To break the tablet, hold the tablet between your thumbs and index fingers close to the appropriate score line. Then, with the score line facing you, apply enough pressure to snap the tablet segments apart (do not use segments that do not break along the score line).<br><br></p>
<p><span class="Bold">Rx only</span><br></p>
<p>U.S. Patent No: 6,958,161<br></p>
<p>Manufactured by:<br>Mayne Pharma International Pty Ltd<br>1538 Main North Road<br>Salisbury South, SA 5106<br>Australia<br>for Warner Chilcott Company, LLC<br>Fajardo, Puerto Rico 00738</p>
<p>Marketed by:<br>Warner Chilcott (US), LLC<br>Rockaway, NJ 07866<br>1-800-521-8813 </p>
<p>0112G1219</p>
<p><img alt="Warner Chilcott logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-14.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_75937110-f370-43e4-bc78-d468987dcb77"></a><a name="section-19"></a><p></p>
<h1>DORYX 100 mg Trade Label   </h1>
<div class="Figure"><img alt="DORYXÂ® (Doxycycline Hyclate Delayed-Release Tablets, USP), 100 mg Trade Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-15.jpg"></div>
<p class="First"><span class="Bold">N</span> 0430-0112-24</p>
<p><span class="Bold">DORYX<span class="Sup">Â®</span><br>(Doxycycline Hyclate Delayed-Release Tablets, USP)</span></p>
<p><span class="Bold">100 mg</span></p>
<p><span class="Bold">Rx only</span></p>
<p>Each tablet contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline.</p>
<p><span class="Bold">100 TABLETS</span><br><img alt="Warner Chilcott logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-16.jpg"></p>
<p>US Patent No. 6,958,161</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_bba5c70c-64b0-47c3-b828-dd9b25a5853d"></a><a name="section-20"></a><p></p>
<h1>DORYX 100 mg Sample Carton Label   </h1>
<div class="Figure"><img alt="DORYXÂ® (doxycycline hyclate) Delayed-Release Tablets, 100 mg Sample Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-17.jpg"></div>
<p class="First"><span class="Bold">N</span> 0430-0112-96</p>
<p><span class="Bold">NEW TABLET DESIGN</span></p>
<p><span class="Bold">NEW TABLET IMPRINT</span></p>
<p><span class="Bold">DORYX<span class="Sup">Â®</span><br>(doxycycline hyclate)<br>Delayed-Release Tablets </span></p>
<p><span class="Bold">100 mg</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">Physician's Sample - NOT FOR SALE</span></p>
<p><span class="Bold">3 Tablets</span></p>
<p>US Patent No. 6,958,161<br><img alt="Warner Chilcott logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-18.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_ea5c36c5-8c49-48ec-bcf9-1d72e09d9210"></a><a name="section-21"></a><p></p>
<h1>DORYX 150 mg Trade Label   </h1>
<p class="First">Â </p>
<div class="Figure"><img alt="DORYXÂ® (doxycycline hyclate delayed-release tablets, USP) 150 mg trade label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-19.jpg"></div>
<p><span class="Bold">N </span>0430-0115-20</p>
<p><span class="Bold">DORYX<span class="Sup">Â®</span><br>(doxycycline hyclate delayed-release tablets, USP)</span></p>
<p><span class="Bold">150 mg</span></p>
<p>Do not chew or crush tablets.</p>
<p>Each tablet contains specially coated pellets of doxycycline hyclate equivalent to 150 mg of doxycycline.</p>
<p>Rx only</p>
<p>60 TABLETS<br><img alt="Warner Chilcott logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-20.jpg"></p>
<p>US Patent No. 6,958,161 <br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_edb4bb01-fa58-4b91-8f8a-f3272780214e"></a><a name="section-22"></a><p></p>
<h1>DORYX 150 mg Sample Carton Label   </h1>
<p class="First">Â Â </p>
<div class="Figure"><img alt=" DORYXÂ® (doxycycline hyclate delayed-release tablets, USP) 150 mg sample carton label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-21.jpg"></div>
<p><span class="Bold">N</span> 0430-0115-95  </p>
<p><span class="Bold">DORYX<span class="Sup">Â®</span><br>(doxycycline hyclate delayed-release tablets, USP)</span></p>
<p><span class="Bold">150 mg per tablet</span></p>
<p>Take with adequate amounts of fluid<br>Do not chew or crush tablets</p>
<p>Rx only    </p>
<p><span class="Bold">Physician's Sample - NOT FOR SALE</span></p>
<p><span class="Bold">3 TABLETS</span></p>
<p>US Patent No. 6,958,161<br><img alt="Warner Chilcott logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-22.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_f860ebfc-9c11-4662-a6b4-8471b09f437c"></a><a name="section-23"></a><p></p>
<h1>DORYX 200 MG Trade Label</h1>
<div class="Figure"><img alt=" DORYXÂ® (doxycycline hyclate delayed-release tablets, USP) 200 mg trade bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-23.jpg"></div>
<p class="First"><span class="Bold">N</span> 0430-0114-20    </p>
<p><span class="Bold">NEW STRENGTH</span></p>
<p><span class="Bold">DORYX<span class="Sup">Â®</span><br>(doxycycline hyclate delayed-release tablets)</span></p>
<p><span class="Bold">200 mg</span></p>
<p><span class="Bold">Rx only</span></p>
<p>Each tablet contains specially coated pellets of doxycycline hyclate equivalent to 200 mg of doxycycline.</p>
<p><span class="Bold">60 TABLETS</span></p>
<p>To report SUSPECTED ADVERSE REACTIONS, contact Warner Chilcott at 1-800-521-8813 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch<br><img alt="Warner Chilcott logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-24.jpg"></p>
<p>US Patent No. 6,958,161</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_4117a088-7912-4658-96c1-198f33294d25"></a><a name="section-24"></a><p></p>
<h1>DORYX 200 MG Sample Carton Label</h1>
<div class="Figure"><img alt=" DORYXÂ® (doxycycline hyclate delayed-release tablets, USP) 200 mg sample carton label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-25.jpg"></div>
<p class="First"><span class="Bold">N</span> 0430-0114-95 </p>
<p><span class="Bold">NEW STRENGTH</span></p>
<p><span class="Bold">DORYX<span class="Sup">Â®</span><br>(doxycycline hyclate delayed-release tablets)</span></p>
<p><span class="Bold">200 mg</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">Physician's Sample - NOT FOR SALE</span></p>
<p><span class="Bold">3 TABLETS</span></p>
<p>To report SUSPECTED ADVERSE REACTIONS, contact Warner Chilcott at 1-800-521-8813 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch<br><img alt="Warner Chilcott logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=37efefc3-cc45-49d1-9dfd-c47d6e6becd5&amp;name=37cd2dae-06b5-4e87-9872-8b5d9c7faabf-26.jpg"></p>
<p>US Patent No. 6,958,161</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DORYXÂ 		
					</strong><br><span class="contentTableReg">doxycycline hyclate tablet, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0430-0112</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DOXYCYCLINE HYCLATE</strong> (DOXYCYCLINE ANHYDROUS) </td>
<td class="formItem">DOXYCYCLINE ANHYDROUS</td>
<td class="formItem">100Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (containing yellow pellets) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">D;1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0430-0112-24</td>
<td class="formItem">48  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0430-0112-96</td>
<td class="formItem">48  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">3  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050795</td>
<td class="formItem">09/01/2005</td>
<td class="formItem">08/01/2011</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DORYXÂ 		
					</strong><br><span class="contentTableReg">doxycycline hyclate tablet, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0430-0115</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DOXYCYCLINE HYCLATE</strong> (DOXYCYCLINE ANHYDROUS) </td>
<td class="formItem">DOXYCYCLINE ANHYDROUS</td>
<td class="formItem">150Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (containing yellow pellets) </td>
<td class="formLabel">Score</td>
<td class="formItem">3 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">RECTANGLE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">D;D;D</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0430-0115-20</td>
<td class="formItem">48  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0430-0115-95</td>
<td class="formItem">48  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">3  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050795</td>
<td class="formItem">09/21/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DORYXÂ 		
					</strong><br><span class="contentTableReg">doxycycline hyclate tablet, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0430-0114</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DOXYCYCLINE HYCLATE</strong> (DOXYCYCLINE ANHYDROUS) </td>
<td class="formItem">DOXYCYCLINE ANHYDROUS</td>
<td class="formItem">200Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (containing yellow pellets) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">D;D</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0430-0114-20</td>
<td class="formItem">48  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0430-0114-95</td>
<td class="formItem">48  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">3  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050795</td>
<td class="formItem">07/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Warner Chilcott (US), LLC
							(957203177)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Mayne Pharma International Pty Ltd</td>
<td class="formItem"></td>
<td class="formItem">756003745</td>
<td class="formItem">MANUFACTURE(0430-0112, 0430-0115, 0430-0114), ANALYSIS(0430-0112, 0430-0115, 0430-0114)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>37cd2dae-06b5-4e87-9872-8b5d9c7faabf</div>
<div>Set id: 37efefc3-cc45-49d1-9dfd-c47d6e6becd5</div>
<div>Version: 8</div>
<div>Effective Time: 20130718</div>
</div>
</div>Â <div class="DistributorName">Warner Chilcott (US), LLC</div></p>
</body></html>
